Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.

We have read with great interest the post hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) randomized trial that investigated effects of liraglutide on incidence of acute gallbladder or biliary disease (uncomplicated gallbladder stones, complicated gallbladder stones, cholecystitis, and biliary obstruction) (1). In this study, time-to-first-event analysis was performed by Cox regression, and it documented increased risk of acute gallbladder or biliary disease with the use of liraglutide compared with placebo (hazard ratio 1.60; 95% CI 1.23, 2.09; P < 0.001). In addition, trends toward the increased incidence were observed for each of the four categories of gallbladder- or biliary tract–related events. Although results of this study …